魯西化工(000830.SZ):2020年擬獲實控人及關聯方提供總額不超20億元財務資助
格隆匯 9 月 28日丨魯西化工(000830.SZ)公佈,公司於2020年9月28日召開的第八屆董事會第八次會議審議通過了《關於接受實際控制人及關聯方提供財務資助的議案》,為支持公司項目建設和增加公司日常經營資金,中國中化集團有限公司(以下簡稱:中化集團)及下屬公司中國中化股份有限公司(以下簡稱:中化股份)2020年擬以現金方式向公司及子公司提供總額不超過20億元(含本數)的財務資助,執行年利率不高於3.85%。據此測算,此次關聯交易金額不超過20.77億元(含本數,其中應支付年利息不超過0.77億元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.